EPRX stock forecast, quote, news & analysis
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals... Show more
Why Eupraxia Pharmaceuticals (EPRX) Stock Is Down -29% in the Last 30 Days
Key Takeaways
- EPRX shares have fallen roughly 29% over the trailing 30 days, declining from about $9.10 on September 30 to approximately $6.42 in late-October trading.
- The pullback gave back much of a sharp September rally, leaving the stock essentially flat — down about 2% — over the trailing quarter.
- Declines came despite a steady stream of positive EP-104GI updates, including 52-week RESOLVE trial data, gastroenterology conference presentations, and completion of the 120-patient Phase 2b enrollment target.
- Several analysts reaffirmed Buy ratings with price targets well above current levels, while a cautious note flagged competition and valuation as limiting factors.
- As a clinical-stage biotech with no meaningful revenue, EPRX trades primarily on clinical catalysts, financing capacity, and sector-wide risk appetite rather than near-term earnings.
- For deeper detail, explore Eupraxia's Price Targets, Earnings, and Forecast pages.
- Traders seeking AI-driven market insights can explore Tickeron's Trending AI Robots.
Eupraxia Pharmaceuticals (EPRX) Company Overview and Market Position
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company headquartered in Victoria, British Columbia, with shares listed on both the Nasdaq and the Toronto Stock Exchange under the ticker EPRX. The company is built around its proprietary Diffusphere™ technology, a polymer-based microsphere platform designed to deliver existing and novel drugs locally and over an extended period, potentially improving safety, tolerability, and duration of effect compared with traditional delivery methods.
Eupraxia's lead programs target areas of high unmet medical need. EP-104GI, a locally injected extended-release formulation of fluticasone propionate, is being evaluated in the Phase 1b/2a open-label and randomized, placebo-controlled Phase 2b portions of the RESOLVE trial for eosinophilic esophagitis (EoE). Its second lead candidate, EP-104IAR for knee osteoarthritis pain, completed a Phase 2b SPRINGBOARD trial that met its primary endpoint and three of four secondary endpoints and has advanced toward late-stage development. Investors follow EPRX primarily for these binary clinical readouts and the large addressable markets they could unlock.
Eupraxia Pharmaceuticals (EPRX) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, EPRX has fallen approximately 29%, from a closing level of $9.10 on September 30 to roughly $6.42 in late-October trading. That decline reflects a sharp reversal from an intraday high near $9.21 reached on September 30, when the company reported 52-week durability data from the highest-dose cohort of its Phase 1b/2a RESOLVE trial.
The quarterly picture is far more muted. Three months earlier, EPRX closed near $6.55 on July 30, meaning the stock is down only about 2% over the trailing quarter. The wide gap between the two figures highlights the stock's volatile path: a rapid September advance that lifted shares from the mid-$6 range to above $9, followed by a broad October retracement that has returned the stock to roughly its early-summer level.
What Drove EPRX Stock Price in the Last 30 Days
The 30-day decline unfolded against a backdrop of otherwise constructive news flow. On September 30, Eupraxia reported that 66% of patients in the highest-dose cohort of the RESOLVE trial maintained clinical remission out to 52 weeks. In early October, analysts at Wedbush, Cantor Fitzgerald, H.C. Wainwright, and Bloom Burton each reaffirmed Buy ratings, with price targets ranging from roughly $11 to $19.
In the weeks that followed, Eupraxia announced that three abstracts from the RESOLVE trial had been accepted for presentation at the American College of Gastroenterology and United European Gastroenterology meetings, and on October 15 it disclosed that it had reached its enrollment target of 120 patients in the blinded Phase 2b portion of the trial. Despite these milestones, shares continued to slide, suggesting the move was driven less by fundamentals than by profit-taking after the September surge, valuation concerns, and competition-focused commentary in the EoE space, compounded by broader pressure on small-cap biotech equities.
What Drove EPRX Stock Performance Over the Last Quarter
Over the trailing three months, EPRX's performance has been defined by a strong, data-driven rally followed by consolidation. Through August and September, accumulating EP-104GI results — including histologic and symptom durability data and the September 30 52-week update — helped lift the stock from the mid-$6 range to a 52-week high above $9. Persistent analyst support, with a consensus rating near "Strong Buy" and price targets implying substantial upside, reinforced that move.
October then saw the stock surrender most of those gains as near-term catalysts were digested. With the pivotal Phase 2b interim readout not expected until December 2026, investors appeared to lock in profits and reassess the risk-reward ahead of the next data catalyst, leaving the stock roughly flat on a quarterly basis even after its sharp 30-day pullback.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that monitor thousands of tickers across the market. Although Tickeron's platform offers hundreds of automated robots, only the top-performing and most relevant strategies appear in this section, helping traders identify active approaches without searching the full catalog. The featured bots vary in strategy, timeframe, and performance metrics, so different options suit different trading styles and risk profiles. The page serves as a discovery tool for investors exploring systematic, data-driven approaches to the market, and traders interested in automation can browse the current lineup to see which strategies are drawing attention.
EPRX Stock Forecast Drivers: What Investors Should Watch Next
The most important near-term catalyst is the interim data readout from the randomized, placebo-controlled Phase 2b portion of the RESOLVE trial, which Eupraxia has guided for December 2026. A virtual Analyst Day scheduled for November 13, 2026, focused on EP-104GI, could also shape sentiment. Investors will additionally monitor progress on EP-104IAR's late-stage development for knee osteoarthritis, the company's cash position and any financing activity, and competitive developments among approved therapies in EoE. Broader factors — including sector risk appetite, interest-rate expectations, and small-cap biotech sentiment — remain relevant given EPRX's clinical-stage profile. These are informational considerations rather than investment recommendations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EPRX in +10.74% Uptrend, advancing for three consecutive days on November 10, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where EPRX advanced for three days, in 101 of 125 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on EPRX as a result. In 61 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for EPRX just turned positive on November 09, 2026. Looking at past instances where EPRX's MACD turned positive, the stock continued to rise in 30 of 39 cases over the following month. The odds of a continued upward trend are 77%.
EPRX moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
EPRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for EPRX crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for EPRX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.213) is normal, around the industry mean (3.498). P/E Ratio (-6.755) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 36 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. EPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology